Oberste M Steven, Moore Deborah, Anderson Barbara, Pallansch Mark A, Pevear Daniel C, Collett Marc S
Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Antimicrob Agents Chemother. 2009 Oct;53(10):4501-3. doi: 10.1128/AAC.00671-09. Epub 2009 Jul 27.
V-073, an enterovirus capsid inhibitor, was evaluated for its spectrum of antipoliovirus activity. V-073 inhibited all 45 polioviruses tested in a virus-induced cytopathic effect protection assay, with 50% effective concentration (EC50) values ranging from 0.003 to 0.126 microM. Ninety percent of the polioviruses tested were inhibited at EC(50)s of < or = 0.076 microM (MIC90 = 32 ng/ml). V-073 is a promising antiviral candidate for the posteradication management of poliovirus incidents.
肠道病毒衣壳抑制剂V-073的抗脊髓灰质炎病毒活性谱得到了评估。在病毒诱导的细胞病变效应保护试验中,V-073抑制了所测试的全部45种脊髓灰质炎病毒,半数有效浓度(EC50)值在0.003至0.126微摩尔之间。90%的测试脊髓灰质炎病毒在EC50≤0.076微摩尔(MIC90 = 32纳克/毫升)时被抑制。V-073是脊髓灰质炎病毒事件根除后管理中一个有前景的抗病毒候选药物。